Pharmacokinetics of different formulations of tioctic (alpha-lipoic) acid in healthy volunteers (Clinical and Experimental Hypertension (2008) 30, (767-775) DOI: 10.1080/10641960802563568);Pharmacokinetics of different formulations of tioctic (alpha-lipoic) acid in healthy volunteers

Clinical and Experimental Hypertension

Volumn 30, Issue 8, 2008, Pages 767-775

  Amenta, Francesco ^a   Traini, Enea ^a   Tomassoni, Daniele ^a   Mignini, Fiorenzo ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Alpha lipoic acid; Cellular concentrations; Different release formulations; Pharmacokinetics; Plasma

Indexed keywords

BYODINORAL 600 QR; GLUTATHIONE; THIOCTACID MG 600 HR; THIOCTIC ACID; TIOBEC 600 RETARD; TIOCRONAL 600 HR; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIOXIDANT ACTIVITY; CONFERENCE PAPER; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYPERTENSION; MALE; NORMAL HUMAN; SINGLE DRUG DOSE;

EID: 56549101218     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960902751402     Document Type: Erratum

References (43)

1. Snell EE, Strong FM, Peterson WH. Growth factors for bacteria. VI: Fractionation and properties of an accessory factor for lactic acid bacteria. Biochem J. 1937;31:1789-1799.
2. Reed LJ. Multienzyme complexes. Acc Chem Res. 1974;7:40-65.
3. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995;19:227-250.
4. Scholich H, Murphy ME, Sies H. Antioxidant activity of dihydrolipoate against microsomal lipid peroxidation and its dependence on alpha-tocopherol. Biochim Biophys Acta. 1989;1001:256-261.
5. Busse E, Zimmer G, Schopohl B, Kornhuber B. Influence of alpha-lipoic acid on intracellular glutathione in vitro and in vivo. Arzneimittelforschung. 1992;42:829-831.
6. Kagan VE, Serbinova EA, Koynova GM, Kitanova SA, Tyurin VA, Stoytchev TS, Quinn PJ, Packer L. Antioxidant action of ubiquinol homologues with different isoprenoid chain length in biomembranes. Free Radic Biol Med. 1990;9:117-126.
7. Jorg J, Metz F, Scharafinski H. Drug treatment of diabetic polyneuropathy with alpha-lipoic acid or vitamin B preparations. A clinical and neurophysiologic study. Nervenarzt. 1988;59:36-44.
8. Ziegler D, Mayer P, Muehlen H, Gries FA. Effekte einer Therapie mit alpha-liponsaeure gegenueber Vitamin B1 bei der diabetischen neuropathie. Diabetes Stoffw. 1993;2:443-447.
9. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A three-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38:1425-1433.
10. Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J, et al. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia. 1997;40:647-653.
11. Ziegler D, Schatz H, Conrad F, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients: A four-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care. 1997;20:369-373.
12. Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes. 1997;46:S62-S66.
13. Borcea V, Nourooz-Zadeh J, Wolff SP, et al. Alpha-lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Radic Biol Med. 1999;26:1495-1500.
14. Haak ES, Usadel KH, Kohleisen M, et al. The effect of alpha-lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy. Microvasc Res. 1999;58:28-34.
15. Rehmann A, Nourooz-Zadeh J, Moller W, et al. Increased oxidative damage to all DNA bases in patients with type II diabetes. FEBS Lett. 1999;448:120-122.
16. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A seven-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999;22:1296-1301.
17. World Medical Association Declaration of Helsinki. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Available at: http://www.idi.it/ ric/ce/helsinki.pdf.
18. Breithaupt-Grögler K, Niebch G, Schneider E, et al. Dose-proportionality of oral thioctic acid - coincidence of assessments via pooled plasma and individual data. Eur J Clin Pharmacol Sci. 1999;8:57-65.
19. Mignini F, Streccioni V, Tomassoni D, Traini E, Amenta F. Comparative crossover, randomised, open-label bioequivalence study on the bioequivalence of two formulations of thioctic acid in healthy volunteers. Clin Exp Hypertens. 2007;29:579-586.
20. European Agency for the Evaluation of Medical Products (EMEA), Committee for Proprietary Medical Products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence. London; 2001. Available at: http://www.emea.europa.eu/pdfs/human/ewp/140198en.pdf.
21. FDA Guidance for Industry. Statistical approaches to establishing bioequivalence. Washington, DC: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2001. Available at: http://www.fda.gov/cder/guidance/3616fnl.pdf.
22. Chen J, Jiang W, Cai J, Tao W, Gao X, Jiang X. Quantification of lipoic acid in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;824:249-257.
23. Hodges JR, Lehmann EL. Estimates of location base on rank tests. Annals of Mathematical Statistics. 1963;34:598-611.
24. Vasdev S, Ford CA, Parai S, Longerich L, Gadag V. Dietary lipoic acid supplementation prevents fructose-induced hypertension in rats. Nutr Metab Cardiovasc Dis. 2000;10:339-346.
25. Vasdev S, Ford CA, Parai S, Longerich L, Gadag V. Dietary alpha-lipoic acid supplementation lowers blood pressure in spontaneously hypertensive rats. J Hypertens. 2000;18:567-573.
26. Vasdev S, Gill V, Longerich L, Parai S, Gadag V. Salt-induced hypertension in WKY rats: prevention by alpha-lipoic acid supplementation. Mol Cell Biochem. 2003;254:319-326.
27. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
28. Noll G, Tschudi M, Nava E, Luscher TF. Endothelium and high blood pressure. Int J Microcirc Clin Exp. 1997;17:273-279.
29. Pechanova O, Kashiba M, Inoue M. Role of glutathione in stabilization of nitric oxide during hypertension developed by inhibition of nitric oxide synthase in the rat. Jpn J Pharmacol. 1999;81:223-229.
30. Zicha J, Dobesova Z, Kunes J. Relative deficiency of nitric oxide-dependent vasodilation in salt-hypertensive Dahl rats: The possible role of superoxide anions. J Hypertens. 2001;19:247-254.
31. Kunes J, Hojna S, Kadlecova M, Dobesova Z, Rauchova H, Vokurkova M, Loukotova J, Pechanova O, Zicha J. Altered balance of vasoactive systems in experimental hypertension: the role of relative NO deficiency. Physiol Res. 2004;53:S23-S34.
32. Pechanova O, Rezzani R, Babal P, Bernatova I, Andriantsitohaina R. Beneficial effects of provinols: Cardiovascular system and kidney. Physiol Res. 2006;55:S17-S30.
33. de Champlain J, Wu R, Girouard H, Karas M, El Midaoui A, Laplante MA, Wu L. Oxidative stress in hypertension. Clin Exp Hypertens. 2004;26:593-601.
34. Teichert J, Kern J, Tritschler HJ, Ulrich H, Preiss R. Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers. Int J Clin Pharmacol Ther. 1998;36:625-628.
35. Teichert J, Tuemmers T, Achenbach H, Preiss C, Hermann R, Ruus P, Preiss R. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease. J Clin Pharmacol. 2005;45:313-328.
36. Hermann R, Wildgrube HJ, Ruus P, Niebch G, Nowak H, Gleiter CH. Gastric emptying in patients with insulin dependent diabetes mellitus and bioavailability of thioctic acid-enantiomers. Eur J Pharm Sci. 1998;6:27-37.
37. Teichert J, Tuemmers T, Achenbach H, Preiss C, Hermann R, Ruus P, Preiss R. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease. J Clin Pharmacol. 2005;45:313-328.
38. Evans JL, Heymann CJ, Goldfine ID, Gavin LA. Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid. Endocr Pract. 2002;8:29-35.
39. Bernkop-Schnürch A, Reich-Rohrwig E, Marschütz M, Schuhbauer H, Kratzel M. Development of a sustained release dosage form for alpha-lipoic acid. II. Evaluation in human volunteers. Drug Dev Ind Pharm. 2004;30:35-42.
40. Packer L, Roy S, Sen CK. Alpha-lipoic acid: A metabolic antioxidant and potential redox modulator of trascription. Adv Pharmacol. 1997;38:79-101.
41. Packer L, Witt E, Tritschler H. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995;19:227-250.
42. Moini H, Tirosh O, Park YC, Cho K-JC, Packer L. R-alpha-lipoic acid action on cell redox status, the insulin receptor and glucose uptake in 3T3-L1 adipocytes. Arch Biochem Biophys. 2002;397:384-391.
43. Han D, Handelman G, Marcocci L, Sen CK, Roy S, Kobuchi H, Tritschler HJ, Flohé L, Packer L. Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization. Biofactors. 1997;6:321-338.